Radiation Recall

 

Radiation recall is a severe skin reaction that occurs when certain chemotherapy drugs are administered during or soon after radiation treatment. The rash appears like a severe sunburn. Treatment generally consists of corticosteroids to reduce inflammation, and rarely, chemotherapy is delayed until the skin heals.

What is radiation recall?

Radiation recall is a severe skin reaction that develops when chemotherapy is administered during or soon after radiation treatment. It usually appears on the area of skin where the radiation was administered several weeks to months after the radiation was administered.

What causes radiation recall?

The chemotherapy drugs that have been reported to cause radiation recall in more than 10 percent of patients include:

  • Cosmegen® (actinomycin)
  • Adriamycin® (doxorubicin)
  • Rheumatrex® (methotrexate)
  • 5-FU (fluorouracil)
  • Hydrea® (hydroxyurea)
  • Taxol® (paclitaxel)
  • Doxil® (liposomal doxorubicin)

What are the symptoms of radiation recall?

Radiation recall is a rash that appears like a severe sunburn. It is characterized by one or more of the following:

  • Redness
  • Tenderness
  • Swelling
  • Wet sores
  • Peeling skin
  • Discoloration after the skin has healed

What is the treatment for radiation recall?

In some cases, symptoms may be severe enough that chemotherapy may have to be delayed until your skin heals. Usually, your doctor will try to give you medication to reduce the inflammation so that you can continue receiving the chemotherapy. Corticosteroids, in the form of a pill or a cream, may be prescribed for this purpose.

What else can I do?

It is very important to protect the skin that is irritated:

  • Stay out of the sun
  • Use sunscreens when you must be exposed
  • Avoid tanning beds
  • Wear loose, nonrestrictive clothing

This content was last modified on August 24, 2007 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health